Category

Archives

Awareness on current status of usage of ritonavir in the management of covid among dental students

Ritonavir's pharmacodynamics raise questions regarding whether medication concentrations high enough to block the SARS-CoV-2 proteases can be obtained. Ritonavir may have a therapeutic benefit at any stage of the disease, although pharmacodynamic issues and the absence of clinical benefit data among hospitalized COVID-19 patients cast doubt on this claim. To study the awareness on current status of usage of ritonavir in the management of COVID among dental students. This study, which is survey-based, involved a sample of 100 individuals and was carried out on the website Survey Planet. The study included undergraduate and graduate dental students. The dental students were given a questionnaire containing 10 questions. Their responses were gathered. The number and percentage were used to summarize the data. Dental students from Chennai showed adequate knowledge of COVID-19 in the medical environment. Postgraduate students were more aware about the current status of usage of Ritonavir for COVID-19. This study demonstrates the urgent necessity for all health-care workers to regularly implement educational interventions and training program on infection control procedures for COVID-19.

 

Comments:

The study found that dental students in Chennai have adequate knowledge of COVID-19 in the medical environment, with postgraduate students being more aware about the current use of ritonavir for COVID-19, highlighting the importance of educational interventions and training programs for healthcare workers on COVID-19 infection control procedures.

Related Products

Cat.No. Product Name Information
S1185 Ritonavir Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis.

Related Targets

P450 (e.g. CYP17) Apoptosis related COVID-19 HIV Protease